Content about Autoimmune diseases

December 7, 2010

Supplier News — Coty officially has announced that it is working with Lady Gaga to develop and market the American pop singer’s first signature fragrance. The yet-to-be named fragrance will launch in spring 2012. Distributed worldwide, the fragrance will be managed by the Coty Beauty division in close collaboration with Lady Gaga, who will be creative director, and her Haus of Gaga team.


November 22, 2010

Aveeno has developed new products and teamed up with the National Eczema Association ...

SKILLMAN, N.J. Aveeno, a Johnson & Johnson Consumer Products brand, has developed new products and teamed up with the National Eczema Association to educate sufferers of the common condition in preparation for the cold and dry winter months when dry skin is most common.

November 21, 2010

Aveeno, a Johnson & Johnson Consumer Products Co. brand, has developed new products and teamed...

SKILLMAN, N.J. Aveeno, a Johnson & Johnson Consumer Products Co. brand, has developed new products and teamed up with the National Eczema Association to educate sufferers of the common condition in preparation for the cold and dry winter months when dry skin is most common.

Roughly 35 million people in the United States suffer from eczema, a chronic skin disorder resulting in intense itching and overall discomfort. Eczema also is among the top five skin conditions for babies zero to 36 months, with 10% to 20% of all infants experiencing some form of eczema.

November 16, 2010

A decision by a Food and Drug Administration advisory committee could pave the way for...

ROCKVILLE, Md. A decision by a Food and Drug Administration advisory committee could pave the way for the first new drug to treat lupus in decades.

 

The FDA’s Arthritis Advisory Committee voted 13-2 Tuesday to recommend approval for Benlysta (belimumab), a drug for systemic lupus erythematosus made by British drug maker GlaxoSmithKline and U.S.-based Human Genome Sciences, the two companies announced. Lupus is an inflammatory disorder that affects internal organs, joints and skin and, in its severest forms, can be fatal.

 

November 15, 2010

A leading charitable funder of and advocate for Type 1 diabetes research and a drug...

NEW YORK and SAN DIEGO — A leading charitable funder of and advocate for Type 1 diabetes research and a drug maker have entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of an analog of the human hormone leptin in patients with Type 1 diabetes.

November 14, 2010

Hugo Naturals, a maker of natural personal care products, has received the gluten-free seal from...

CHATSWORTH, Calif. — Hugo Naturals, a maker of natural personal care products, has received the gluten-free seal from the Celiac Sprue Association, designating the company's full range of products as gluten-free and appropriate for the growing population with celiac disease.

 

November 7, 2010

Patients with rheumatoid arthritis derive about as much benefit from a weekly injection of a...

NEW YORK Patients with rheumatoid arthritis derive about as much benefit from a weekly injection of a biotech drug made by Bristol-Myers Squibb for the disease as they do from receiving it via IV on a monthly basis, according to late-stage clinical trial data released Monday.

October 17, 2010

Weight-management products company Smart for Life has developed a diet cookie for those with gluten...

BOCA RATON, Fla. Weight-management products company Smart for Life has developed a diet cookie for those with gluten sensitivity.

The gluten-free banana chocolate chip granola square has no preservatives and is made with many organic ingredients and a balanced protein formula with healthy fats and carbohydrate ratios. As with all Smart for Life products, this gluten-free line also effectively suppresses the appetite, the company said.

October 12, 2010

Supervalu's Cub Foods is looking to help customers with gluten sensitivity with the launch of...

October 4, 2010

The drug market for ulcerative colitis treatments will see modest growth through 2019, according to...

BURLINGTON, Mass. The drug market for ulcerative colitis treatments will see modest growth through 2019, according to a new report by Decision Resources.

The research and advisory firm said that the UC drug market will see growth of $800 million, driven by the uptake of Abbott and Eisai's Humira, Centocor Ortho Biotech/Merck/Mitsubishi Tanabe Pharma/Janssen's Simponi and Millennium's vedolizumab in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

September 30, 2010

Teva Pharmaceutical Industries and Active Biotech announced promising results from a mid-stage trial of laquinimod,...

September 28, 2010

The drug market for Crohn's disease treatments will see moderate growth over the next decade,...

BURLINGTON, Mass. The drug market for Crohn's disease treatments will see moderate growth over the next decade, Decision Resources reported Wednesday.

The research firm projected that the market will increase a little more than 31%, from $3.2 billion in 2009 to $4.2 billion in 2019, in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Decision Resources said the the modest growth rate masks such market changes as new and emerging biologics, as well as generic competition.

September 21, 2010

The Food and Drug Administration has approved a drug for reducing relapses in patients with...

SILVER SPRING, Md. The Food and Drug Administration has approved a drug for reducing relapses in patients with multiple sclerosis.

 

The FDA announced Wednesday the approval of Swiss drug maker Novartis’ Gilenia (fingolimod) capsules, saying it was the first oral drug that can slow the progression of disability in patients with MS and offered an alternative to injected drugs.

 

 

Around 400,000 people in the United States and 2.1 million worldwide have MS, according to the National Multiple Sclerosis Society.

September 12, 2010

At the ECRM Health Care EPPS conference, OcuSoft presented a pair of new offerings. Drug...

At the ECRM Health Care EPPS conference, OcuSoft presented a pair of new offerings. Drug Store News caught up with OcuSoft president and CEO Cynthia Barratt for a rundown on eye care today.

Drug Store News: What is the opportunity within eyelid cleansers?

September 9, 2010

Efforts by two generic drug makers to market a generic version of a drug for...

NEW YORK Efforts by two generic drug makers to market a generic version of a drug for multiple sclerosis hit an obstacle this week in a U.S. District Court.

 

The U.S. District Court for the Southern District of New York denied a motion for summary judgment filed by Sandoz and Momenta Pharmaceuticals that patents covering Teva Pharmaceutical Industries’ drug Copaxone (glatiramer acetate) are invalid due to indefiniteness.

 

 

August 22, 2010

The cultivation of cereals for human consumption helped give rise to the first civilizations, but...

August 18, 2010

The Food and Drug Administration has decided to expedite the review of an investigational drug...

July 22, 2010

An investigational drug for rheumatoid arthritis reduced the duration of symptoms in patients over the...

July 13, 2010

The market for multiple sclerosis drugs, long dominated by biologics and injectables, soon could see...

June 14, 2010

The Food and Drug Administration has agreed to speed up the review of a Genzyme...

June 13, 2010

An advisory committee of the Food and Drug Administration unanimously recommended approval for an investigational...

June 13, 2010

Teva Pharmaceutical Industries has invested $11.9 million in Andromeda Biotech, a company that develops diabetes...

June 6, 2010

Cetaphil, a Galderma Laboratories brand of cleansers and moisturizers, is launching a sub-brand that is...

June 6, 2010

Gluten-free products continue to gain ground in the snack food aisle, but drug chains have...

June 2, 2010

German drug maker Bayer HealthCare Pharmaceuticals has created an iPhone application that it called the...